When did Sutro Biopharma report Q4 2024 earnings?

Sutro Biopharma (STRO) reported Q4 2024 earnings on March 13, 2025 before market open.

What were Sutro Biopharma's Q4 2024 revenue and EPS?

Sutro Biopharma reported revenue of $14.8M and diluted EPS of $-0.89 for Q4 2024.

Did Sutro Biopharma beat estimates in Q4 2024?

Revenue beat the consensus estimate of $12.2M by $2.7M. EPS missed the consensus estimate of $-0.86 by $0.03.

Where can I find Sutro Biopharma's Q4 2024 SEC filings?

You can read the 10-K periodic report (0000950170-25-038884) directly on SEC EDGAR. The filing index links above go to sec.gov.

Sutro Biopharma STRO Q4 2024 Annual earnings

Reported March 13, 2025 · Before market open

Revenue$14.8MBeat by $2.7M Diluted EPS-$0.89Miss by $0.03

Revenue estimate$12.2M

EPS estimate-$0.86

Next report

Aug 6, 2026 (In 3 weeks)

Revenue estimate$11.8M

EPS estimate-$2.22

Financials

Q4 2024

Income statement

See full

Revenue$14.8M-87.0%

Operating income-$65.3M—

Net income-$72.4M—

EPS (diluted)-$27.33—

Balance sheet

See full

Cash & equivalents$190.3M+175%

Total debt$23.2M-31.2%

Total equity$44.6M-70.2%

Total assets$387.2M-17.7%

Cash flow

See full

Operating cash flow-$71.7M—

Free cash flow-$71.7M—

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$151.72M-42.0%

Enterprise value-$15.43M-107%

P/S2.4×+0.7×

Profitability

See full

Operating margin-384.3%—

Net margin-366.6%—

FCF margin-325.2%—

Returns & leverage

See full

Return on equity-234.2%—

Debt / equity0.5×+0.3×

Current ratio2.6×-1.9×

Segments

By product

See full

Ongoing Performance Related To Unsatisfied Performance Obligations$6.0M+7.0%

Financing Component On Unearned Revenue$1.1M-52.1%

Materials Supply$1.1M+72.4%

Research And Development Services$922.0K-52.6%

Versus estimates

Revenue

Q1 2026$14.5MBeat by $5.6M Q4 2025$11.7MBeat by $2.4M Q3 2025$9.7MMiss by $450.5K Q2 2025$63.7MBeat by $54.8M Q1 2025$17.4MBeat by $2.4M

Q4 2024$14.8MBeat by $2.7M

Diluted EPS

Q1 2026-$2.94Miss by $0.62 Q4 2025-$5.29Beat by $2.87 Q3 2025-$6.70Miss by $2.50 Q2 2025-$0.14Beat by $0.25 Q1 2025-$0.91Miss by $0.28

Q4 2024-$0.89Miss by $0.03

Ask the moment Sutro Biopharma reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Sutro Biopharma report Q4 2024 earnings?: Sutro Biopharma (STRO) reported Q4 2024 earnings on March 13, 2025 before market open.
What were Sutro Biopharma's Q4 2024 revenue and EPS?: Sutro Biopharma reported revenue of $14.8M and diluted EPS of $-0.89 for Q4 2024.
Did Sutro Biopharma beat estimates in Q4 2024?: Revenue beat the consensus estimate of $12.2M by $2.7M. EPS missed the consensus estimate of $-0.86 by $0.03.
Where can I find Sutro Biopharma's Q4 2024 SEC filings?: You can read the 10-K periodic report (0000950170-25-038884) directly on SEC EDGAR. The filing index links above go to sec.gov.